BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Paraganglioma industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Prostate Biopsy Devices industry to provide essential data & information for the targeted readers.

Increasing incidence of chronic and rare diseases, growing demand for personalized medicine, and rising availability of funds by private and public sectors for cell based research activities in developed countries are some factors expected to drive global Cell Expansion market growth.

Rising cases of cancer worldwide and increasing government initiatives to raise cancer awareness among the population are some of the key factors expected to drive Immunocytokines market revenue growth.

According to the most recent analysis by Emergen Research, the global market for microbial bioremediation had a value of USD 46,865.2 million in 2021 and is projected to grow at a rate of 11.0 percent during the forecast period.

The company will focus in the coming months on negotiating a Series A round of €7 million to finance market entry, complete clinical validation and expand the product portfolio.

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the database lock for the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease.

Viz.ai, the leading AI-powered disease detection and intelligent care coordination platform, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural (SDH).

No hospital has a monopoly on good ideas. This is why the St. Baldrick’s Foundation funds the most promising research — no matter where it takes place – from your backyard institution to other cutting edge research facilities treating childhood cancers around the globe.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy.